- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05532059
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma
November 14, 2023 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
A Phase Ⅱ, Open Label, Single-center Study of Lenvatinib and Tirelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts.
Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to undergo surgery.
As more effective and novel chemotherapy, targeted therapies, and immunotherapy become available, multiple treatments can be chosen for the patients with advanced CCA.
Cytotoxic cell death during tumor chemotherapy triggers antigen release and induces strong anti-tumor effects of T cells.
Tyrosine kinase inhibitors (TKI) can reduce the expression of PD-L1 and inhibit Treg cell infiltration, and together with immune checkpoint inhibitors, they can relieve tumor immunosuppressive microenvironment.
Therefore,we aim to investigate the safety and efficacy of lenvatinib, tislelizumab combined with gemcitabine plus cisplatin (GPLET) in the treatment of advanced cholangiocarcinoma.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- weilin wang, doctor
- Phone Number: +86 0571 87783820
- Email: wam@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically proven, unresectable advanced or metastatic cholangiocarcinoma patients.
- the world health organization (WHO)/ECOG physical state (PS) to 0 or 1.
- at least 1 RECIST 1.1 standard target lesions.
- not previously received immunotherapy, including but not limited to CTLA 4, PD-L1 or/and PD-1 inhibitors.
- adequate organ and bone marrow function, defined as follows: 9.0 g/dL or higher hemoglobin; neutrophil count 1.5 x 109 / L; platelet count 100 x 109 / L.
Exclusion Criteria:
- Active or previously documented autoimmune disease or inflammatory disease.
- Uncontrolled complications.
- History of other primary malignancies.
- Active infection.
- Women who are pregnant or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GPLET
intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8; oral lenvatinib 8 mg/day (<60kg) or 12 mg/ d(≥60kg)from days 1 to 21; intravenous tislelizumab 200 mg on day 15
|
Lenvatinib, tislelizumab, gemcitabine and cisplatin
|
Active Comparator: GP
intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8
|
gemcitabine and cisplatin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective remission rate (ORR)
Time Frame: 4 cycle treatment (each cycle is 21 days)
|
According to RECIST v1.1, the proportion of patients with at least one complete response (CR) or partial response (PR) (%)
|
4 cycle treatment (each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival (PFS)
Time Frame: From date of randomization until the date of first documented progression, assessed up to 60 months
|
The time between the date of randomization and the date of radiographic progression as defined by RECIST1.1
|
From date of randomization until the date of first documented progression, assessed up to 60 months
|
Overall survival time (OS)
Time Frame: From date of randomization until the date of death from any cause, assessed up to 60 months
|
The time between the date of randomization and death from any cause
|
From date of randomization until the date of death from any cause, assessed up to 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2022
Primary Completion (Estimated)
August 31, 2025
Study Completion (Estimated)
August 31, 2028
Study Registration Dates
First Submitted
August 22, 2022
First Submitted That Met QC Criteria
September 5, 2022
First Posted (Actual)
September 8, 2022
Study Record Updates
Last Update Posted (Estimated)
November 17, 2023
Last Update Submitted That Met QC Criteria
November 14, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Cholangiocarcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Cisplatin
- Lenvatinib
- Gemcitabine
- Tislelizumab
Other Study ID Numbers
- 20220901
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cholangiocarcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
-
Fudan UniversityRecruitingAdvanced Intrahepatic CholangiocarcinomaChina
-
HutchmedRecruitingAdvanced Intrahepatic CholangiocarcinomaChina
-
Institut de Recherches Internationales ServierCompletedMetastatic Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States, Spain, Korea, Republic of, Italy, France, United Kingdom
-
National Science and Technology Development Agency...Khon Kaen UniversityUnknownAdvanced Intrahepatic CholangiocarcinomaThailand
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
Tyra Biosciences, IncRecruitingSolid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced CholangiocarcinomaUnited States
-
Aiwu Ruth He, MDMerck Sharp & Dohme LLC; Georgetown University; The Cleveland Clinic; Hoosier Cancer... and other collaboratorsTerminatedAdvanced CholangiocarcinomaUnited States
-
Jiangmen Central HospitalUnknownAdvanced CholangiocarcinomaChina
Clinical Trials on Lenvatinib, tislelizumab, gemcitabine and cisplatin
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor...RecruitingAdvanced CholangiocarcinomaChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandDanish Lymphoma GroupRecruitingHodgkin LymphomaNetherlands, Belgium, Denmark
-
Tianjin Medical University Cancer Institute and...Not yet recruitingResectable Hepatocellular Carcinoma
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Guangxi Medical UniversityNot yet recruitingRecurrence | Hepatocellular Carcinoma | Immune Checkpoint InhibitorChina
-
Nanjing Leads Biolabs Co.,LtdRecruiting
-
Zhejiang Cancer HospitalRecruitingHepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | PharmorubicinChina
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Tianjin Medical University Cancer Institute and...RecruitingPotentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder CancerChina